ClinicalTrials.gg
TerminatedNCT02807454FUSIONMM-003Updated Feb 21, 2023Results posted

A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma

A Phase 2 interventional study of Daratumumab and Durvalumab in Multiple Myeloma, sponsored by Celgene. Terminated at 64 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-21.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Why this study was terminated
Health Authority request due to class effect

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
37
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 132 studies testing daratumumab in Multiple Myeloma — 21 open to participants now, 63 under way, 10 of them phase 3. daratumumab · Multiple Myeloma.

Enrollment
87th of 132
37 · median 50
Started
2016
with 6 others
Phase 2
73 of 132
7 open now
Registered
15th of 132
by date
Lead sponsor
3 of 132
Celgene

Among the 132 studies testing daratumumab in Multiple Myeloma, this one is the 87th largest by enrollment, is one of 7 that started in 2016, is one of 73 in phase 2, and was the 15th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

21 of the 132 studies testing daratumumab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About daratumumab

daratumumab: first FDA approval 2015 (DARZALEX), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies testing daratumumab in Multiple Myeloma, or all of them as a file.
02

Study summary

This is an open-label, multicenter study to confirm the safety and efficacy of durvalumab + daratumumab (D2) in subjects with relapsed and refractory multiple myeloma. This study will also explore the safety and efficacy of the addition of pomalidomide + dexamethasone to durvalumab + daratumumab (PD3).

On 05 Sep 2017, a Partial Clinical Hold was placed on this study by the United States (US) Food and Drug Administration (FDA). The decision by the FDA was based on data related to risks of anti-programmed cell death-1 (PD-1) antibody, pembrolizumab, in combination with IMiDs® immunomodulatory drugs in patients with multiple myeloma. As a result, enrollment into this study has been discontinued. Subjects who are receiving clinical benefit, based on the discretion of the investigator, may remain on study treatment after being reconsented.

03

Conditions studied

  • Multiple Myeloma

Keywords

  • Phase 2
  • Open-Label
  • Durvalumab
  • Daratumumab
  • Multiple Myeloma
  • Relapsed and Refractory (RRMM)
  • FUSION MM-003
  • PD-L1
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have as defined by m-protein or serum free light chain.
  • Must have failed last ( to last line of treatment).
  • Must have achieved at least a minimal response (MR) to at least 1 prior anti-myeloma regimen before developing PD (relapsed)
  • Has performance status of 0, 1, or 2 on the (ECOG) Performance Scale
  • Must be at least 18 years of age

Exclusion criteria

Exclusion Criteria:

  • Has non-secretory multiple myeloma
  • Has had prior anti-myeloma therapy within 2 weeks prior to study Day 1
  • Has received prior therapy with an anti-programmed cell death 1 receptor (), antiprogrammed death-ligand 1 (anti-PD-L1), anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways).
  • Has received prior treatment with daratumumab or other anti-CD38 therapies previously
  • Has undergone prior organ or allogeneic hematopoetic stem cell transplantation
  • Has received stem cell transplantation (ASCT) within 12 weeks before the date of randomization.
  • Has received prior treatment with a monoclonal antibody within 5 half-lives of Study Day 1
  • Has received agents within 28 days or 5 half-lives (whichever is longer) of Study Day 1
  • Has received live, attenuated vaccine within 30 days prior to Study Day 1
  • Has (COPD) with a (FEV1) 50% of predicted normal
  • Has moderate or severe persistent asthma within the past 2 years or uncontrolled asthma of any classification.
  • Is positive for (HIV), chronic or active or active hepatitis A or C
  • Has a prior history of , other than MM, unless the subject has been free of the disease for ≥ 5 years (with the exception Basal cell carcinoma of the skin, Squamous cell carcinoma of the skin, Carcinoma in situ of the cervix, Carcinoma in situ of the breast, Incidental histologic finding of prostate cancer [T1a or T1b] or prostate cancer that is curative)
  • Has clinical evidence of central nervous system (CNS) or pulmonary leukostasis, disseminated intravascular coagulation, or CNS multiple myeloma
  • Has cardiac disease
  • Is a female who is pregnant, nursing, or breastfeeding, or who intends to become pregnant during the participation in the study
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    Daratumumab Plus Durvalumab Treatment

    * Intravenous (IV) durvalumab at 1500mg on Day 1 or 2 of a 28-day cycle * IV daratumumab at 16mg/kg on days 1, 8, 15 and 22 at cycles 1-2; on days 1 and 15 at cycles 3-6; and on day 1 from cycle 7 onward

    Drug: Daratumumab · Drug: Durvalumab

  • Experimental
    Pomalidomide+ Daratumumab+ Durvalumab+ Dexamethasone Treatment

    * Intravenous (IV) durvalumab at 1500mg on Day 1 or 2 of a 28-day cycle * IV daratumumab at 16mg/kg on days 1, 8, 15 and 22 at cycles 1-2; on days 1 and 15 at cycles 3-6; and on day 1 from cycle 7 onward * oral POM at 4mg/day on days 1 to 21 * oral/IV dex at 40mg/day (\>75 years old) or 20mg/day (\>75 years old) on days 1, 8, 15 and 22

    Drug: Daratumumab · Drug: Durvalumab · Drug: Pomalidomide · Drug: Dexamethasone

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    Tumor response of partial response (PR) or better was assessed using the International Myeloma Working Group (IMWG) Uniform Response Criteria. ORR was calculated as the percent of responders (multiplied by 100). Partial response required ≥ 50% reduction of serum M-Protein and reduction in 24-hour urinary M protein by ≥ 90% or to \< 200 mg per 24 hours.

    Time frame: From first dose to up to approximately 66 months

  2. Number of Participants With Adverse Events (AEs)

    Number of participants who experienced at least one adverse event. An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values, regardless of etiology. Any worsening (i.e., any clinically significant adverse change in the frequency or intensity of a preexisting condition should be considered an AE.

    Time frame: From first dose to 90 days after last dose (up to approximately 58 months)

  3. Number of Participants With Serious Adverse Events (SAEs)

    Number of participants who experienced at least one serious adverse event. An SAE is any AE occurring at any dose that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, constitutes an important medical event.

    Time frame: From first dose to 90 days after last dose (up to approximately 58 months)

Secondary outcomes

  1. Time-To-Response (TTR)

    Time-to-response is calculated as the time from enrollment to the first date of documented response (partial response or better). Tumor response of partial response (PR) or better was assessed using the International Myeloma Working Group (IMWG) Uniform Response Criteria. Partial response required ≥ 50% reduction of serum M-Protein and reduction in 24-hour urinary M protein by ≥ 90% or to \< 200 mg per 24 hours. For those participants where POM + DEX were added, time-to-response was calculated from the date POM and DEX were added to the first date of documented response (PR or better).

    Time frame: From enrollment to earliest documented response (up to approximately 66 months)

  2. Kaplan-Meier Estimate of Duration of Response (DOR) - Simon Stage 1: D2 Arm

    Duration of response was calculated as the time from the earliest date of documented response (PR or better) to the earliest date of disease progression as determined by the investigator. For those participants where POM + DEX was added, duration of response was calculated as the time from the earliest date of documented response after POM + DEX was added (PR or better) to the earliest date of disease. Tumor response of partial response (PR) or better was assessed using the International Myeloma Working Group (IMWG) Uniform Response Criteria. Partial response required ≥ 50% reduction of serum M-Protein and reduction in 24-hour urinary M protein by ≥ 90% or to \< 200 mg per 24 hours. Progressive Disease required increase of 25% from lowest response value in the serum M-component (absolute increase must be ≥ 0.5 g/dL) and/or urine M-component (absolute increase must be ≥ 200 mg/24 h).

    Time frame: From the earliest date of documented response (PR or better) to earliest date of progressive disease (up to approximately 66 months)

  3. Kaplan-Meier Estimate of Duration of Response (DOR) - PD3 Arm

    Duration of response was calculated as the time from the earliest date of documented response (PR or better) to the earliest date of disease progression as determined by the investigator. For those participants where POM + DEX was added, duration of response was calculated as the time from the earliest date of documented response after POM + DEX was added (PR or better) to the earliest date of disease progression as determined by the investigator. Participants who are alive or lost to follow-up will be censored on the last-known-to-be-alive date. Tumor response of partial response (PR) or better was assessed using the International Myeloma Working Group (IMWG) Uniform Response Criteria. Partial response required ≥ 50% reduction of serum M-Protein and reduction in 24-hour urinary M protein by ≥ 90% or to \< 200 mg per 24 hours.

    Time frame: From the earliest date of documented response (PR or better) to earliest date of progressive disease (up to approximately 66 months)

  4. Kaplan-Meier Estimate of Progression-Free Survival (PFS) - Simon Stage 1: D2 Arm

    Progression-free survival was calculated as the time between the enrollment to the first documentation of progressive disease or death from any cause during study, whichever occurs earlier using the International Myeloma Working Group (IMWG) Uniform Response Criteria. Progressive Disease required increase of 25% from lowest response value in the serum M-component (absolute increase must be ≥ 0.5 g/dL) and/or urine M-component (absolute increase must be ≥ 200 mg/24 h).

    Time frame: From enrollment to first documentation of progressive disease or death from any cause during study, whichever occurs earlier (up to approximately 66 months)

  5. Kaplan-Meier Estimate of Progression-Free Survival (PFS) - PD3 Arm

    Progression-free survival was calculated as the time between the enrollment to the first documentation of progressive disease or death from any cause during study, whichever occurs earlier using the International Myeloma Working Group (IMWG) Uniform Response Criteria. Progressive Disease required increase of 25% from lowest response value in the serum M-component (absolute increase must be ≥ 0.5 g/dL) and/or urine M-component (absolute increase must be ≥ 200 mg/24 h).

    Time frame: From enrollment to first documentation of progressive disease or death from any cause during study, whichever occurs earlier (up to approximately 66 months)

  6. Maximum Observed Plasma Concentration (Cmax) - Simon Stage 1: D2 Arm

    Pharmacokinetics of Durvalumab derived from serum concentration versus time data.

    Time frame: Cycle 1 - Days 2, 8, 15, 22

  7. Time of Maximum Observed Concentration (Tmax) - Simon Stage 1: D2 Arm

    Pharmacokinetics of Durvalumab derived from serum concentration versus time data.

    Time frame: Cycle 1 - Days 2, 8, 15, 22

  8. Area Under the Plasma Concentration-Time Curve to the Last Measurable Plasma Concentration [AUC(0-Last)] - Simon Stage 1: D2 Arm

    Pharmacokinetics of Durvalumab derived from serum concentration versus time data.

    Time frame: Cycle 1 - Days 2, 8, 15, 22

  9. Area Under the Plasma Concentration-Time Curve in 1 Dosing Interval [AUC(TAU)] - Simon Stage 1: D2 Arm

    Pharmacokinetics of Durvalumab derived from serum concentration versus time data.

    Time frame: Cycle 1 - Days 2, 8, 15, 22

07

Results

Posted Feb 21, 2023
Limitations and caveats
This study stopped enrolling participants on 05-Sep-2017 and was terminated earlier than planned on 03-Jan-2022. This results disclosure report provides outputs from the Simon Stage 1: D2 and PD3 arms. Simon Stage 2: D2 did not enroll any participants.

Participant flow

Participant flow — Overall Study
MilestoneSimon Stage 1: D2 ArmPD3 Arm
Started325
Participants in the d2 arm who also received pomalidomide + dexamethasone70
Completed00
Not completed325
Withdrew: Adverse event10
Withdrew: Withdrawal by subject01
Withdrew: Progressive disease303
Withdrew: Other reasons11

Outcome measures

PrimaryOverall Response Rate (ORR)

Tumor response of partial response (PR) or better was assessed using the International Myeloma Working Group (IMWG) Uniform Response Criteria. ORR was calculated as the percent of responders (multiplied by 100). Partial response required ≥ 50% reduction of serum M-Protein and reduction in 24-hour urinary M protein by ≥ 90% or to \< 200 mg per 24 hours.

Time frame:
From first dose to up to approximately 66 months
Reported as:
Number · Percentage of participants
Overall Response Rate (ORR)
Percentage of participantsSimon Stage 1: D2 ArmPD3 Arm
Overall Response Rate (ORR)53.175.0
PrimaryNumber of Participants With Adverse Events (AEs)

Number of participants who experienced at least one adverse event. An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values, regardless of etiology. Any worsening (i.e., any clinically significant adverse change in the frequency or intensity of a preexisting condition should be considered an AE.

Time frame:
From first dose to 90 days after last dose (up to approximately 58 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsSimon Stage 1: D2 ArmPD3 Arm
Number of Participants With Adverse Events (AEs)315
PrimaryNumber of Participants With Serious Adverse Events (SAEs)

Number of participants who experienced at least one serious adverse event. An SAE is any AE occurring at any dose that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, constitutes an important medical event.

Time frame:
From first dose to 90 days after last dose (up to approximately 58 months)
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs)
ParticipantsSimon Stage 1: D2 ArmPD3 Arm
Number of Participants With Serious Adverse Events (SAEs)172
SecondaryTime-To-Response (TTR)

Time-to-response is calculated as the time from enrollment to the first date of documented response (partial response or better). Tumor response of partial response (PR) or better was assessed using the International Myeloma Working Group (IMWG) Uniform Response Criteria. Partial response required ≥ 50% reduction of serum M-Protein and reduction in 24-hour urinary M protein by ≥ 90% or to \< 200 mg per 24 hours. For those participants where POM + DEX were added, time-to-response was calculated from the date POM and DEX were added to the first date of documented response (PR or better).

Time frame:
From enrollment to earliest documented response (up to approximately 66 months)
Reported as:
Median · Weeks
Time-To-Response (TTR)
WeeksSimon Stage 1: D2 ArmSimon Stage 1: D2 + Pomalidomide + DexamethasonePD3 Arm
Time-To-Response (TTR)4.29 (4.0 to 12.0)5.07 (4.1 to 8.1)8.14 (4.3 to 8.3)
SecondaryKaplan-Meier Estimate of Duration of Response (DOR) - Simon Stage 1: D2 Arm

Duration of response was calculated as the time from the earliest date of documented response (PR or better) to the earliest date of disease progression as determined by the investigator. For those participants where POM + DEX was added, duration of response was calculated as the time from the earliest date of documented response after POM + DEX was added (PR or better) to the earliest date of disease. Tumor response of partial response (PR) or better was assessed using the International Myeloma Working Group (IMWG) Uniform Response Criteria. Partial response required ≥ 50% reduction of serum M-Protein and reduction in 24-hour urinary M protein by ≥ 90% or to \< 200 mg per 24 hours. Progressive Disease required increase of 25% from lowest response value in the serum M-component (absolute increase must be ≥ 0.5 g/dL) and/or urine M-component (absolute increase must be ≥ 200 mg/24 h).

Time frame:
From the earliest date of documented response (PR or better) to earliest date of progressive disease (up to approximately 66 months)
Reported as:
Median · Months
Kaplan-Meier Estimate of Duration of Response (DOR) - Simon Stage 1: D2 Arm
MonthsSimon Stage 1: D2 ArmSimon Stage 1: D2 + Pomalidomide + Dexamethasone
Kaplan-Meier Estimate of Duration of Response (DOR) - Simon Stage 1: D2 Arm8.31 (3.7 to 11.1)8.41 (3.7 to 12.0)
SecondaryKaplan-Meier Estimate of Duration of Response (DOR) - PD3 Arm

Duration of response was calculated as the time from the earliest date of documented response (PR or better) to the earliest date of disease progression as determined by the investigator. For those participants where POM + DEX was added, duration of response was calculated as the time from the earliest date of documented response after POM + DEX was added (PR or better) to the earliest date of disease progression as determined by the investigator. Participants who are alive or lost to follow-up will be censored on the last-known-to-be-alive date. Tumor response of partial response (PR) or better was assessed using the International Myeloma Working Group (IMWG) Uniform Response Criteria. Partial response required ≥ 50% reduction of serum M-Protein and reduction in 24-hour urinary M protein by ≥ 90% or to \< 200 mg per 24 hours.

Time frame:
From the earliest date of documented response (PR or better) to earliest date of progressive disease (up to approximately 66 months)
Reported as:
Median · Months
Kaplan-Meier Estimate of Duration of Response (DOR) - PD3 Arm
MonthsPD3 Arm
Kaplan-Meier Estimate of Duration of Response (DOR) - PD3 Arm7.62 (6.7 to 17.5)
SecondaryKaplan-Meier Estimate of Progression-Free Survival (PFS) - Simon Stage 1: D2 Arm

Progression-free survival was calculated as the time between the enrollment to the first documentation of progressive disease or death from any cause during study, whichever occurs earlier using the International Myeloma Working Group (IMWG) Uniform Response Criteria. Progressive Disease required increase of 25% from lowest response value in the serum M-component (absolute increase must be ≥ 0.5 g/dL) and/or urine M-component (absolute increase must be ≥ 200 mg/24 h).

Time frame:
From enrollment to first documentation of progressive disease or death from any cause during study, whichever occurs earlier (up to approximately 66 months)
Reported as:
Median · Months
Kaplan-Meier Estimate of Progression-Free Survival (PFS) - Simon Stage 1: D2 Arm
MonthsSimon Stage 1: D2 ArmSimon Stage 1: D2 + Pomalidomide + Dexamethasone
Kaplan-Meier Estimate of Progression-Free Survival (PFS) - Simon Stage 1: D2 Arm5.74 (2.0 to 6.5)8.05 (3.7 to 12.9)
SecondaryKaplan-Meier Estimate of Progression-Free Survival (PFS) - PD3 Arm

Progression-free survival was calculated as the time between the enrollment to the first documentation of progressive disease or death from any cause during study, whichever occurs earlier using the International Myeloma Working Group (IMWG) Uniform Response Criteria. Progressive Disease required increase of 25% from lowest response value in the serum M-component (absolute increase must be ≥ 0.5 g/dL) and/or urine M-component (absolute increase must be ≥ 200 mg/24 h).

Time frame:
From enrollment to first documentation of progressive disease or death from any cause during study, whichever occurs earlier (up to approximately 66 months)
Reported as:
Median · Months
Kaplan-Meier Estimate of Progression-Free Survival (PFS) - PD3 Arm
MonthsPD3 Arm
Kaplan-Meier Estimate of Progression-Free Survival (PFS) - PD3 Arm9.02 (6.9 to 18.5)
SecondaryMaximum Observed Plasma Concentration (Cmax) - Simon Stage 1: D2 Arm

Pharmacokinetics of Durvalumab derived from serum concentration versus time data.

Time frame:
Cycle 1 - Days 2, 8, 15, 22
Reported as:
Geometric mean · ug/mL
Maximum Observed Plasma Concentration (Cmax) - Simon Stage 1: D2 Arm
ug/mLSimon Stage 1: D2 Arm
Maximum Observed Plasma Concentration (Cmax) - Simon Stage 1: D2 Arm315.806 ± 34.832
SecondaryTime of Maximum Observed Concentration (Tmax) - Simon Stage 1: D2 Arm

Pharmacokinetics of Durvalumab derived from serum concentration versus time data.

Time frame:
Cycle 1 - Days 2, 8, 15, 22
Reported as:
Median · Hour
Time of Maximum Observed Concentration (Tmax) - Simon Stage 1: D2 Arm
HourSimon Stage 1: D2 Arm
Time of Maximum Observed Concentration (Tmax) - Simon Stage 1: D2 Arm1.150 (1.03 to 1.83)
SecondaryArea Under the Plasma Concentration-Time Curve to the Last Measurable Plasma Concentration [AUC(0-Last)] - Simon Stage 1: D2 Arm

Pharmacokinetics of Durvalumab derived from serum concentration versus time data.

Time frame:
Cycle 1 - Days 2, 8, 15, 22
Reported as:
Geometric mean · Hour*ug/mL
Area Under the Plasma Concentration-Time Curve to the Last Measurable Plasma Concentration [AUC(0-Last)] - Simon Stage 1: D2 Arm
Hour*ug/mLSimon Stage 1: D2 Arm
Area Under the Plasma Concentration-Time Curve to the Last Measurable Plasma Concentration [AUC(0-Last)] - Simon Stage 1: D2 Arm77831.751 ± 48.535
SecondaryArea Under the Plasma Concentration-Time Curve in 1 Dosing Interval [AUC(TAU)] - Simon Stage 1: D2 Arm

Pharmacokinetics of Durvalumab derived from serum concentration versus time data.

Time frame:
Cycle 1 - Days 2, 8, 15, 22
Reported as:
Geometric mean · Hour*ug/mL
Area Under the Plasma Concentration-Time Curve in 1 Dosing Interval [AUC(TAU)] - Simon Stage 1: D2 Arm
Hour*ug/mLSimon Stage 1: D2 Arm
Area Under the Plasma Concentration-Time Curve in 1 Dosing Interval [AUC(TAU)] - Simon Stage 1: D2 Arm83966.099 ± 46.115

Adverse events

Collected over All-cause mortality was assessed from the participant's first dose to their study completion (up to approximately 66 months). SAEs and Other AEs were assessed from first dose to 90 days after last dose of study therapy (up to approximately 58 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Simon Stage 1: D2 Arm11/32 (34.4%)17/32 (53.1%)31/32 (96.9%)
PD3 Arm4/5 (80%)2/5 (40%)5/5 (100%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventSimon Stage 1: D2 ArmPD3 Arm
SepsisInfections and infestations0/322/5
PneumoniaInfections and infestations7/321/5
Febrile neutropeniaBlood and lymphatic system disorders1/321/5
General physical health deteriorationGeneral disorders3/320/5
PyrexiaGeneral disorders2/320/5
DiarrhoeaGastrointestinal disorders1/320/5
DeathGeneral disorders1/320/5
FatigueGeneral disorders1/320/5
Oedema peripheralGeneral disorders1/320/5
HepatitisHepatobiliary disorders1/320/5
Most frequent other events
Showing 10 of 101
Most frequent other events
EventSimon Stage 1: D2 ArmPD3 Arm
Back painMusculoskeletal and connective tissue disorders7/324/5
AnaemiaBlood and lymphatic system disorders16/323/5
NeutropeniaBlood and lymphatic system disorders15/323/5
DiarrhoeaGastrointestinal disorders9/323/5
Upper respiratory tract infectionInfections and infestations3/323/5
ThrombocytopeniaBlood and lymphatic system disorders7/322/5
NauseaGastrointestinal disorders8/322/5
FatigueGeneral disorders4/322/5
Respiratory tract infectionInfections and infestations6/322/5
Neutrophil count decreasedInvestigations0/322/5

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Simon Stage 1: D2 ArmPD3 ArmTotal
Mean63.2 ± 7.5863 ± 5.6663.2 ± 7.29
Sex: Female, Male
Sex: Female, Male(Participants)Simon Stage 1: D2 ArmPD3 ArmTotal
Female13114
Male19423
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Simon Stage 1: D2 ArmPD3 ArmTotal
Hispanic or Latino000
Not Hispanic or Latino32537
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Simon Stage 1: D2 ArmPD3 ArmTotal
White31536
Other101
08

Study locations

64 sites
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • UCLA Division of Hematology Oncology
    Los Angeles, California 90095-1752, United States
  • Colorado Blood Cancer Institute
    Denver, Colorado 80218, United States
  • Local Institution - 007
    Denver, Colorado 80218, United States
  • Emory University Hospital
    Atlanta, Georgia 30322, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Center For Cancer and Blood Disorders
    Bethesda, Maryland 20817, United States
  • Dana-Farber Partners Cancer Care, Inc.
    Boston, Massachusetts 02115, United States
  • Washington University
    Saint Louis, Missouri 63110, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Perelman Center for Advanced Medicine
    Philadelphia, Pennsylvania 19104, United States
  • University of Pennsylvania - Perelman Center for Advanced Medicine
    Philadelphia, Pennsylvania 19104, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • Tennessee Oncology Nashville Drug Development Unit
    Nashville, Tennessee 37203, United States
  • Swedish Medical Center
    Seattle, Washington 98104, United States
  • AZ St-Jan Brugge Oostende AV
    Brugge, 8000, Belgium
  • Universitaire Ziekenhuizen Leuven Univeristy Hospitals Leuven
    Leuven, B-3000, Belgium
  • Cliniques Universitaires UCL de Mont-Godine
    Yvoir, 5530, Belgium
  • Local Institution - 103
    Saint John, New Brunswick E2L 3L6, Canada
  • Saint John Regional Hospital
    Saint John, New Brunswick E2L 3L6, Canada
  • Local Institution - 104
    Toronto, Ontario M5G 2M9, Canada
  • Princess Margaret Cancer Centre
    Toronto, Ontario M5G 2M9, Canada
  • Hopital Maisonneuve-Rosemont
    Montreal, Quebec H1T 2M4, Canada
  • Local Institution - 101
    Montreal, Quebec H1T 2M4, Canada
  • MUHC Glen Site
    Montreal, Quebec H4A 3J1, Canada
  • Local Institution - 552
    Copenhagen, 2100, Denmark
  • Rigshospitalet University Hospital
    Copenhagen, 2100, Denmark
  • Local Institution - 553
    Odense, DK-5000, Denmark
  • Odense University Hospital
    Odense, DK-5000, Denmark
  • Local Institution - 551
    Vejle, 7100, Denmark
  • Vejle Hospital
    Vejle, 7100, Denmark
  • Universitatsklinikum Carl Gustav Carus an der TU Dresden
    Dresden, 01307, Germany
  • Local Institution - 203
    Heidelberg, 69115, Germany
  • Universitatsklinikum Heidelberg
    Heidelberg, 69115, Germany
  • University Hospital Tubingen
    Tubingen, 72076, Germany
  • Local Institution - 201
    Wuerzburg, 97080, Germany
  • Universitatsklinikum Wuerzburg
    Wuerzburg, 97080, Germany
  • Local Institution - 354
    Bologna, 40138, Italy
  • Policlinico S. Orsola - Malpighi
    Bologna, 40138, Italy
  • A.O.U. Maggiore della Carità
    Novara, 28100, Italy
  • Local Institution - 353
    Novara, 28100, Italy
  • Azienda Ospedaliera di Padova
    Padova, 35128, Italy
  • Local Institution - 355
    Padova, 35128, Italy
  • Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello
    Palermo, 90146, Italy
  • A.O. Universitaria Ospedale S.Chiara Dip.Oncologia, Div. Ematologia
    Pisa, 56126, Italy
  • Hospital Durán i Reynals - Instituto Catalàn de Oncologìa ICO
    Barcelona, 08907, Spain
  • Local Institution - 453
    Barcelona, 08907, Spain
  • Hospital de Cabuenes
    Gijon, 33394, Spain
  • Local Institution - 451
    Gijon, 33394, Spain
  • Hospital Universitario Fundacion Jimenez Diaz
    Madrid, 28040, Spain
  • Local Institution - 452
    Madrid, 28040, Spain
  • Hospital 12 de Octubre
    Madrid, 28041, Spain
  • Sahlgrenska University Hospital
    Gothenburg, 60 Gothenburg, Sweden
  • Local Institution - 501
    Lund, 221 85, Sweden
  • Skanes Universitetssjukhus Malmo
    Lund, 221 85, Sweden
  • Local Institution - 502
    Stockholm, SE-141 86, Sweden
  • Karolinska Universitetssjukhuset - Huddinge
    Stockholm, SE-14186, Sweden
  • St. Bartholomew's and The Royal London Hospital
    London, EC1A 7BE, United Kingdom
  • Christie Hospital
    Manchester, M20 4BX, United Kingdom
  • Local Institution - 252
    Oxford, 0X3 7LE, United Kingdom
  • Oxford University Hospitals NHS Trust- Churchill Hospital-Oxford Centre for Respiratory Medicine
    Oxford, 0X3 7LE, United Kingdom
  • Local Institution - 253
    Sutton (Surrey), SM2 5PT, United Kingdom
  • Royal Marsden Hospital
    Sutton (Surrey), SM2 5PT, United Kingdom
  • The Royal Wolverhampton Hospital NHS Trust
    Wolverhampton, WV10 0QP, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2016 to primary completion in Jan 2022, 65 months.

Results were first posted in Feb 2023, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2016
First posted
Jun 21, 2016
StartActual
Jul 7, 2016
Primary completionActual
Jan 3, 2022
CompletionActual
Jan 3, 2022
Results first posted
Feb 21, 2023
Last update
Feb 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02807454
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Jun 21, 2016
Start date
Jul 7, 2016
Primary completion
Jan 3, 2022
Completion
Jan 3, 2022
Results posted
Feb 21, 2023
Last update
Feb 21, 2023

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Daratumumab · Durvalumab

Start the discussion